Drug-coated balloons in below-the-knee arteries

• Verfasst von: Stoll, Felicitas E. [VerfasserIn]
• Verfasst von: Uslu, Reyhan [VerfasserIn]
• Verfasst von: Blessing, Erwin [VerfasserIn]
• Verfasst von: Frey, Norbert [VerfasserIn]
• Verfasst von: Katus, Hugo [VerfasserIn]
• Verfasst von: Erbel, Christian [VerfasserIn]
• Verfasst von: Heilmeier, Britta [VerfasserIn]
• Verfasst von: Müller, Oliver J. [VerfasserIn]
• Titel: Drug-coated balloons in below-the-knee arteries
• Titelzusatz: analysis of a real-world data set
• Verf.angabe: Felicitas Stoll, Reyhan Uslu, Erwin Blessing, Norbert Frey, Hugo A. Katus, Christian Erbel, Britta Heilmeier and Oliver J. Müller
• E-Jahr: 2022
• Jahr: May 23, 2022
• Umfang: 7 S.
• Fussnoten: Gesehen am 27.02.2023
• Titel Quelle: Enthalten in: Vasa
• Ort Quelle: Bern : Huber, 1995
• Jahr Quelle: 2022
• Band/Heft Quelle: 51(2022), 4, Seite 256-262
• ISSN Quelle: 1664-2872
• DOI: doi:10.1024/0301-1526/a001009
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: critical limb ischemia
• Sach-SW: Drug-coated balloon
• Sach-SW: interventional treatment
• Sach-SW: peripheral artery disease
• K10plus-PPN: 183761881X

Abstract

Summary:Background: The search for an optimal interventional treatment strategy in infrapopliteal peripheral artery disease remains in the focus of interest. Whether drug-coated balloons (DCB) might enhance interventional outcomes after crural interventions is a matter of debate, as studies yielded conflicting results on DCB safety and efficacy. Patients and methods: We analyzed a retrospective cohort of 75 infrapopliteal DCB interventions performed at our institution in 68 patients with peripheral artery disease in Rutherford category 3 to 6. Results: Despite a high rate of long complex lesions and multi-vessel disease, freedom from clinically driven target lesions revascularization (TLR) after 365 days was 68%. After six months, healing or significant improvement of the ischemic ulcer was observed in 78% of cases. Accordingly, freedom from major amputation and death after 365 days was 82%. Freedom from major amputation and death was 76.2% of cases in patients with diabetes mellitus as opposed to 91.5% in patients without diabetes mellitus (p=0.049). Conclusions: With this real-world analysis we would like to contribute to the ongoing discussion on the benefit and safety of DCB treatment in below-the-knee interventions.